Japan to Buy 1.6 Mill Courses of Merck’s Oral COVID-19 Antiviral Molnupiravir
Merck (MRK) and Ridgeback Biotherapeutics have announced that the Japanese government will acquire approximately 1.6 million courses of molnupiravir (MK-4482,
Read moreMerck (MRK) and Ridgeback Biotherapeutics have announced that the Japanese government will acquire approximately 1.6 million courses of molnupiravir (MK-4482,
Read moreThe world’s most vulnerable populations are given access to COVID-19 vaccines thanks to the COVAX Humanitarian Buffer. Johnson & Johnson
Read moreThe novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read moreMerck and Ridgeback’s Molnupiravir has become the world’s first approved oral COVID-19 antiviral drug. Molnupiravir has been authorised by the
Read moreThe U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0,
Read moreFrench pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read moreThe US Food and Drug Administration has granted approval for administration of COVID-19 vaccine booster dosage, upgrading the emergency use
Read moreThe World Health Organization on Wednesday endorsed the groundbreaking GlaxoSmithKline Malaria vaccine for children at risk reinvigorating the fight against
Read moreInterim Analysis of Phase 3 Study shows Merck and Ridgeback’s investigational oral antiviral Molnupiravir has reduced the risk of hospitalization
Read morePfizer and BioNTech reported that data from their COVID-19 vaccine Phase 2/3 study in children aged 5 to 12 years
Read more